Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Dyslipidemia

Free Subscription Articles published in Curr Opin Lipidol Retrieve available abstracts of 35 articles: HTML format

Single Articles

October 2022
1. SCIPIONE CA, Cybulsky MI
   Early atherogenesis: new insights from new approaches.
   Curr Opin Lipidol. 2022;33:271-276.
   PubMed     Abstract available
   
   
   August 2022
2. MARTINS J, Rossouw HM, Pillay TS
   How should low-density lipoprotein cholesterol be calculated in 2022?
   Curr Opin Lipidol. 2022;33:237-256.
   PubMed     Abstract available
   
   
   July 2022
3. LEREN TP, Bogsrud MP
   Cascade screening for familial hypercholesterolemia should be organized at a national level.
   Curr Opin Lipidol. 2022 Jul 13. pii: 00041433-990000000-00004.
   PubMed     Abstract available
   
   
   
4. DURRINGTON PN, Bashir B, Bhatnagar D, Soran H, et al
   Lipoprotein (a) in familial hypercholesterolaemia.
   Curr Opin Lipidol. 2022 Jul 13. pii: 00041433-990000000-00005.
   PubMed     Abstract available
   
   
   
5. PAQUETTE M, Bernard S, Baass A
   Diagnosis of remnant hyperlipidaemia.
   Curr Opin Lipidol. 2022 Jul 13. pii: 00041433-990000000-00002.
   PubMed     Abstract available
   
   
   June 2022
6. THEROND P, Chapman MJ
   Sphingosine-1-phosphate: metabolism, transport, atheroprotection and effect of statin treatment.
   Curr Opin Lipidol. 2022;33:199-207.
   PubMed     Abstract available
   
   
   April 2022
7. WHITTAKER MN, Musunuru K
   Therapeutic application of genome editing in dyslipidemia.
   Curr Opin Lipidol. 2022;33:133-138.
   PubMed     Abstract available
   
   
   February 2022
8. SACKS FM, Andraski AB
   Dietary fat and carbohydrate affect the metabolism of protein-based high-density lipoprotein subspecies.
   Curr Opin Lipidol. 2022;33:1-15.
   PubMed     Abstract available
   
   
   December 2021
9. ANTONIAZI L, Arroyo-Olivares R, Mata P, Santos RD, et al
   Association of dietary patterns and components with atherosclerosis risk biomarkers in familial hypercholesterolemia.
   Curr Opin Lipidol. 2021 Dec 13. pii: 00041433-900000000-99240.
   PubMed     Abstract available
   
   
   
10. MEDEIROS AM, Bourbon M
    Polygenic contribution for familial hypercholesterolemia (FH).
    Curr Opin Lipidol. 2021;32:392-395.
    PubMed     Abstract available
    
    
    
11. CHAN DC, Ying Q, Watts GF
    Recent dynamic studies of the metabolism of atherogenic lipoproteins: elucidating the mode of action of new therapies.
    Curr Opin Lipidol. 2021;32:378-385.
    PubMed     Abstract available
    
    
    
12. MATA P, Alonso R, Perez de Isla L, Badimon L, et al
    Dyslipidemia and aortic valve disease.
    Curr Opin Lipidol. 2021;32:349-354.
    PubMed     Abstract available
    
    
    
13. KERSTEN S
    ANGPTL3 as therapeutic target.
    Curr Opin Lipidol. 2021;32:335-341.
    PubMed     Abstract available
    
    
    October 2021
14. GILL PK, Hegele RA
    Familial combined hyperlipidemia is a polygenic trait.
    Curr Opin Lipidol. 2021 Oct 22. pii: 00041433-900000000-99252.
    PubMed     Abstract available
    
    
    
15. MCINTOSH CS, Watts GF, Wilton SD, Aung-Htut MT, et al
    Splice correction therapies for familial hypercholesterolemic patients with low-density lipoprotein receptor mutations.
    Curr Opin Lipidol. 2021 Oct 15. pii: 00041433-900000000-99253.
    PubMed     Abstract available
    
    
    
16. GRAHAM DF, Raal FJ
    Management of familial hypercholesterolemia in pregnancy.
    Curr Opin Lipidol. 2021 Oct 6. pii: 00041433-900000000-99256.
    PubMed     Abstract available
    
    
    September 2021
17. THOMPSON GR
    Use of apheresis in the age of new therapies for familial hypercholesterolaemia.
    Curr Opin Lipidol. 2021 Sep 22. pii: 00041433-900000000-99259.
    PubMed     Abstract available
    
    
    August 2021
18. IQBAL Z, Bashir B, Ferdousi M, Kalteniece A, et al
    Lipids and peripheral neuropathy.
    Curr Opin Lipidol. 2021;32:249-257.
    PubMed     Abstract available
    
    
    
19. DRON JS, Hegele RA
    Editorial: Discussing polygenic risk with lipid clinic patients.
    Curr Opin Lipidol. 2021;32:273-275.
    PubMed    
    
    
    June 2021
20. BERBERICH AJ, Hegele RA
    Lipid effects of glucagon-like peptide 1 receptor analogs.
    Curr Opin Lipidol. 2021;32:191-199.
    PubMed     Abstract available
    
    
    April 2021
21. MOHAMED F, Botha TC, Raal FJ
    Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia.
    Curr Opin Lipidol. 2021 Apr 20. pii: 00041433-900000000-99277.
    PubMed     Abstract available
    
    
    
22. PULIPATI VP, Davidson MH
    The clinical black, white, and gray lessons.
    Curr Opin Lipidol. 2021;32:151-156.
    PubMed     Abstract available
    
    
    
23. WAND H, Knowles JW, Clarke SL
    The need for polygenic score reporting standards in evidence-based practice: lipid genetics use case.
    Curr Opin Lipidol. 2021;32:89-95.
    PubMed     Abstract available
    
    
    
24. BROWN EE
    The genetic counselor's role in management of patients with dyslipidemia.
    Curr Opin Lipidol. 2021;32:83-88.
    PubMed     Abstract available
    
    
    
25. TRINDER M, Brunham LR
    Polygenic scores for dyslipidemia: the emerging genomic model of plasma lipoprotein trait inheritance.
    Curr Opin Lipidol. 2021;32:103-111.
    PubMed     Abstract available
    
    
    
26. FONG V, Patel SB
    Recent advances in ABCG5 and ABCG8 variants.
    Curr Opin Lipidol. 2021;32:117-122.
    PubMed     Abstract available
    
    
    February 2021
27. CHORA JR, Bourbon M
    Pharmacogenomics of statins and familial hypercholesterolemia.
    Curr Opin Lipidol. 2021 Feb 10. pii: 00041433-900000000-99283.
    PubMed     Abstract available
    
    
    October 2020
28. YEANG C, Willeit P, Tsimikas S
    The interconnection between lipoprotein(a), lipoprotein(a) cholesterol and true LDL-cholesterol in the diagnosis of familial hypercholesterolemia.
    Curr Opin Lipidol. 2020 Oct 6. doi: 10.1097/MOL.0000000000000713.
    PubMed     Abstract available
    
    
    
29. IBRAHIM S, Reeskamp LF, Stroes ESG, Watts GF, et al
    Advances, gaps and opportunities in the detection of familial hypercholesterolemia: overview of current and future screening and detection methods.
    Curr Opin Lipidol. 2020 Oct 6. doi: 10.1097/MOL.0000000000000714.
    PubMed     Abstract available
    
    
    September 2020
30. WOLSKA A, Yang ZH, Remaley AT
    Hypertriglyceridemia: new approaches in management and treatment.
    Curr Opin Lipidol. 2020 Sep 29. doi: 10.1097/MOL.0000000000000710.
    PubMed     Abstract available
    
    
    June 2020
31. SORAN H, Cooper JA, Durrington PN, Capps N, et al
    Non-HDL or LDL cholesterol in heterozygous familial hypercholesterolaemia: findings of the Simon Broome Register.
    Curr Opin Lipidol. 2020 Jun 28. doi: 10.1097/MOL.0000000000000692.
    PubMed     Abstract available
    
    
    
32. BELANGER AM, Akioyamen L, Alothman L, Genest J, et al
    Evidence for improved survival with treatment of homozygous familial hypercholesterolemia.
    Curr Opin Lipidol. 2020 Jun 8. doi: 10.1097/MOL.0000000000000686.
    PubMed     Abstract available
    
    
    April 2020
33. BRANDTS J, Dharmayat KI, Ray KK, Vallejo-Vaz AJ, et al
    Familial hypercholesterolemia: is it time to separate monogenic from polygenic familial hypercholesterolemia?
    Curr Opin Lipidol. 2020 Apr 22. doi: 10.1097/MOL.0000000000000675.
    PubMed     Abstract available
    
    
    
34. BAJAJ A, Cuchel M
    Homozygous familial hypercholesterolemia: what treatments are on the horizon?
    Curr Opin Lipidol. 2020 Apr 22. doi: 10.1097/MOL.0000000000000677.
    PubMed     Abstract available
    
    
    January 2020
35. D'ERASMO L, Di Costanzo A, Arca M
    Autosomal recessive hypercholesterolemia: update for 2020.
    Curr Opin Lipidol. 2020 Jan 31. doi: 10.1097/MOL.0000000000000664.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Dyslipidemia is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: